This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Based in New Haven, CT, Alexion Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of life-transforming drugs, for the treatment of patients with ultra-rare disorders. The company’s complement franchise consists of key growth driver, Soliris, which is approved for the treatment of two severe and ultra-rare disorders resulting from chronic uncontrolled activation of the complement component of the immune system — paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Soliris is also approved for the treatment of generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody-positive. The FDA also approved its long-acting C5 complement inhibitor, Ultomiris, for the treatment of adult patients with PNH, to be administered every eight weeks. In October 2019, the FDA approved the use of Ultomiris as a treatment for adult and pediatric (one month of age or older) patients with aHUS to inhibit complement-mediated TMA.
Will Strong HIV Sales Drive Gilead's (GILD) Q3 Earnings?
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Gilead (GILD) reports third-quarter 2019 results.
What's in Store for Thermo Fisher (TMO) in Q3 Earnings?
by Zacks Equity Research
Developments in business segments are likely to have aided Thermo Fisher (TMO) in the third quarter.
Alexion to Buy Achillion for $930M, Strengthen PNH Franchise
by Zacks Equity Research
Alexion (ALXN) will buy Achillion for $930 million to strengthen its PNH franchise.
Alexion Pharmaceuticals (ALXN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Alexion (ALXN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Alexion Pharmaceuticals (ALXN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (ALXN) Outperforming Other Medical Stocks This Year?
Alexion (ALXN) Collaborates With Stealth BioTherapeutics
by Zacks Equity Research
Alexion (ALXN) teams up with Stealth BioTherapeutics for a late-stage therapy for mitochondrial diseases.
3 Big Drug/Biotech Stocks Set to Beat Q3 Earnings Estimates
by Kinjel Shah
Here we highlight three bigshot drug/biotech companies, which are expected to deliver positive earnings surprises in Q3.
ALXN vs. CBM: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ALXN vs. CBM: Which Stock Is the Better Value Option?
Alexion (ALXN) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Alexion (ALXN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Alexion (ALXN) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
Alexion (ALXN) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Why Alexion is a Hot Takeover Target in the Biotech Sector
by Zacks Equity Research
Let's take a look at the factors, which make Alexion (ALXN) a hot target for a takeover amid the M&A wave in the pharma/biotech sector.
Will Alexion (ALXN) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Alexion (ALXN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Achillion's Danicopan Gets Breakthrough Therapy Tag for PHN
by Zacks Equity Research
Achillion's (ACHN) oral factor D inhibitor, danicopan, receives Breakthrough Therapy designation from the FDA as a treatment option for PNH. Shares up.
3 Reasons Growth Investors Will Love Alexion (ALXN)
by Zacks Equity Research
Alexion (ALXN) could produce exceptional returns because of its solid growth attributes.
3 Big Biotech Stocks Worth Adding to Your Portfolio Now
by Ekta Bagri
We highlight a few key biotech stocks that surpass the sector so far in 2019 and are likely to witness a winning run in the near term.
Alexion (ALXN) Down on News of CFO Clancy's Departure in 2019
by Zacks Equity Research
Alexion's (ALXN) shares decline, following the news of the departure of its current chief financial officer, Paul Clancy.
Biotech Stock Roundup: BIIB Halts AD Study, AMGN Posts Positive MM Drug Data & More
by Zacks Equity Research
Key highlights of the past week include regulatory and pipeline updates, acquisition deals, and more.
Akari's Nomacopan Gets Orphan Drug Tag for Rare Skin Disease
by Zacks Equity Research
The FDA grants orphan drug status to Akari's (AKTX) nomacopan for the treatment of bullous pemphigoid, a severe blistering skin condition.
Zacks.com featured highlights include: Columbia Sportswear, Fossil Group, Alexion and Shoe Carnival
by Zacks Equity Research
Zacks.com featured highlights include: Columbia Sportswear, Fossil Group, Alexion and Shoe Carnival
ALXN or CBM: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ALXN vs. CBM: Which Stock Is the Better Value Option?
Rising P/E: An Often-Ignored Trick to Pick 5 Winning Stocks
by Sanghamitra Saha
Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.
Biotech Stock Roundup: AMGN's Lung Cancer Candidate, ALXN's Deal With Eidos in Focus
by Zacks Equity Research
Key highlights of the past week include regulatory and pipeline updates, and licensing deals and more.
Alexion (ALXN) In-licenses Amyloidosis Candidate In Japan
by Zacks Equity Research
Alexion (ALXN) strengthens its amyloidosis portfolio with an exclusive license secured from Eidos to develop and commercialize an investigational small molecule AG10 in Japan.
Amgen's KRAS Inhibitor Shows Response in Larger NSCLC Group
by Zacks Equity Research
Amgen's (AMGN) novel investigational KRAS inhibitor, AMG 510, for solid tumor shows anti-tumor activity in a larger group of NSCLC patients.
Has Alexion Pharmaceuticals (ALXN) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (ALXN) Outperforming Other Medical Stocks This Year?